{"url_path":"/sec/fblg/8-k/2026-06-29/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-288468-index.html","accession_number":"0001193125-26-288468","cik":"0001958777","ticker":"FBLG","issuer_name":"FibroBiologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-288468-index.html","primary_entity_key":"0001958777","primary_entity_name":"FibroBiologics, Inc."},"word_count":349,"has_tables":true,"body_markdown":"Item 3.02 Unregistered Sales of Equity Securities.\n\n \n\nThe disclosure set forth above in Item 1.01 of this Form 8-K relating to (i) the issuance of the Pre-Funded Warrants and Warrants to the Purchaser pursuant to the Securities Purchase Agreement, including the Shares of Common Stock to be issued in connection with exercises of the Pre-Funded Warrants and Warrants, and (ii) the issuance of the Placement Agent Warrants to the Placement Agent (or its designees) pursuant to the Engagement Letter, including the Shares of Common Stock to be issued in connection with exercises of the Placement Agent Warrants, is incorporated by reference herein in its entirety.\n\n \n\nThe maximum number of Shares of Common Stock that may be issued through the exercise of the Pre-Funded Warrants is 4,081,633, subject to customary anti-dilution adjustments. The maximum number of Shares of Common Stock that may be issued through the exercise of the Warrants is 8,163,266, subject to customary anti-dilution adjustments. The maximum number of Shares of Common Stock that may be issued through the exercise of the Placement Agent Warrants is 285,714, subject to customary anti-dilution adjustments.\n\n \n\nThe offer and sale of the Pre-Funded Warrants, Warrants and Shares of Common Stock to be issued in connection with exercises of the Pre-Funded Warrants and Warrants pursuant to the Securities Purchase Agreement and the offer and sale of the Placement Agent Warrants and the Shares of Common Stock to be issued in connection with exercises of the Placement Agent Warrants pursuant to the Engagement Letter was and will be made in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D of the Securities Act and in reliance on similar exemptions under applicable state laws. This Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state."}